Propofol-based total intravenous anesthesia: Propofol-based total intravenous anesthesia, titrated to clinical need.
Sevoflurane intravenous anesthesia: Sevoflurane intravenous anesthesia, titrated to clinical need.
Study summary
The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
* Primary esophageal cancer without known extension beyond the esophagus. (i.e. believed to be Tumor Stage 1-3).
* Scheduled for potentially curative esophageal cancer surgery.
* Written informed consent, including willingness to be randomized to intravenous versus volatile anesthesia.
Exclusion Criteria:
* Previous surgery for esophageal cancer (except diagnostic biopsies) Age \<18 or \>85 years old.
* ASA Physical Status ≥4.
* Any contraindication to propofol or sevoflurane.
* Other cancer not believed by the attending surgeon to be in long-term remission.
* Systemic disease believed by the attending surgeon to present ≥25% two- year mortality.
Primary outcome measure(s)
Recurrence-free survival — 4 years Patients who did not experience cancer recurrence and/or death.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.